(Q39618095)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Richard D Barry

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Darren R Shafren

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

21 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

568-581

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

Global cancer statistics in the year 2000.

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Experiments on the spread of colds: II. Studies in volunteers with coxsackievirus A21

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

PRODUCTION OF ILLNESS WITH A SMALL-PARTICLE AEROSOL OF COXSACKIE A21

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Acute respiratory disease in normal volunteers associated with Coxsackie A-21 viral infection. III. Response to nasopharyngeal and enteric inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Potent oncolytic activity of human enteroviruses against human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

China approves world's first oncolytic virus therapy for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

A novel and rapid method to quantify cytolytic replication of picornaviruses in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Recent advances in adjuvant therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9614-0

Supportive and palliative care of pancreatic cancer.

21 January 2018

1 reference

12 December 2020

Oncolytic reovirus against ovarian and colon cancer.

1 reference

12 December 2020

Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.

1 reference

12 December 2020

Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment.

1 reference

12 December 2020

Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity

1 reference

12 December 2020

Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration

1 reference

12 December 2020

Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor

1 reference

12 December 2020

Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21.

1 reference

12 December 2020

A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin

1 reference

12 December 2020

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

12 December 2020

10.1007/S10637-010-9614-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170760%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference